Edition:
United Kingdom

Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial Of CTP-692 As An Adjunctive Treatment For Schizophrenia


Wednesday, 10 Apr 2019 

April 10 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS INITIATES PHASE 1 MULTIPLE-ASCENDING DOSE TRIAL OF CTP-692 AS AN ADJUNCTIVE TREATMENT FOR SCHIZOPHRENIA.CONCERT PHARMACEUTICALS INC - TOPLINE DATA FROM BOTH SINGLE-AND MULTIPLE-ASCENDING CTP-692 PHASE 1 TRIALS ARE EXPECTED IN Q2 OF 2019.CONCERT PHARMACEUTICALS INC - CTP-692 WAS FOUND TO BE WELL TOLERATED IN HEALTHY VOLUNTEERS.CONCERT PHARMACEUTICALS INC - NO SERIOUS ADVERSE EVENTS WERE REPORTED. 

Company Quote

11.22
0.17 +1.54%
17 Jul 2019